The Secretariat accepts students on weekdays from 12:00 - 13:30


Study Guide 2019-20

Antimisiaris Sophia PDF Print
Tel.: (+30) 2610 962332

E-mailThis e-mail address is being protected from spambots. You need JavaScript enabled to view it                                                                                              


Current Position

  • Professor of Pharmaceutics, Department of Pharmacy, University of Patras, 26500 Rio, Greece
  • Director, Laboratory of Pharmaceutical Technology, University of Patras, Greece
  • Collaborating Faculty member, Institute of Chemical Engineering, ICEHT/FORTH




Google Scholar:



Place and Date of Birth

New Jersey, USA, 1962

Marital Status

Married, two children


Rio 26510, Greece



+30-2610-962332 mob:6937503020

This e-mail address is being protected from spambots. You need JavaScript enabled to view it ; This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Education / Affiliations
1980-1984: Dept. of Pharmacy, University of Athens, GR. Degree: BPharm (8.4/10)
 1984-1988: Dept of Pharmacy, University of Athens, GR. Degree: PhD (Biopharmaceutics, Excellent)
 1988-1989: Postdoc Research Assistant, Laboratory of Prof. Karl H.L.Hwang, School of Pharmacy, University of South California; LA, USA
 1989-1993: Lecturer of Pharmaceutics, University of Patras (UPAT);
 1992-1993: Visiting Professor, Research associate, Laboratory of Prof. Gregory Gregoriadis, Centre for Drug Delivery Research (CDDR), School of Pharmacy, University of London; UK.
 1993-2002: Assistant Prof. Dept. of Pharmacy, UPAT;
 2002-10: Associate Prof. Dept of Pharmacy, UPAT;
 2006-: Collaborating Member, Institute of Chemical Engineering, ICEHT-FORTH;
 2010-: Professor, Department of Pharmacy, UPAT (procedure was repeated in 2012 due to administrative problems).
 Research Activities
  •  Nanomedicines for Controlled/Targeted Drug Delivery; Innovative nanomedicines Bio-Inspired from Extracellular vesicles;
  • Improving Drug Pharmacokinetics through Advanced Drug Delivery (Liposomal) System Design;
  • Novel Controlled-(Release)-Drug-Eluting Surfaces for Bioactive agents, Antimicrobials, etc;
  • Platform systems for Ocular, Alveolar and Vaginal Drug Delivery Systems, for sustained release of drugs that act locally;
  • Elastic Liposomes for penetration in the skin;
  • Nanoparticles for Brain targeting, for Cancer or Alzheimer’s disease, diagnosis and/or therapy;
  • Improving the anticancer properties of therapeutics by development of targeted carrier systems, with inherit anticancer properties;
  • Biocompatible nanoparticles for sustained release of therapeutics/bioactive agents during bone regeneration;
Participation in Research Projects-FUNDING
  • 1989-2002 Participation in several working groups of the Department of Pharmacy for the preparation of proposals for funding of educational/research activities.
  • PENED 1997 (General Secretariat of Research and Technology), “Study of Biophysical properties of arsonolopids and arsonoliposomes”, 1997-2000 Role: PI; Collaboration with Prof. P.V. Ioannou, and Prof. G. Tsivgoulis, Department of Chemistry, University of Patras.
  • FP6/ Marie Curie Early Stage Scholarship Program, “Towards a Euro-PhD in Advanced drug delivery”, contract no: MEST-CT-2004 - 504992 (FP6) [2004-2008, Host lab with 3 one-year scholarships (120.000 € for SGA)] (Role: PI, Host Lab of three PhD students from Europe) More info. about Collaborations at
  • Socrates mobility and Intensive Program Training Projects (1997- 2008; total~70.000 €. Role:PI )
  • FP6/ Integrated Project (Health) LSHP-CT-2004-503162 “Selection and Development of Microbicides for Mucosal Use to Prevent Sexual HIV Transmission/Acquisition” SHIVA 2004-2009 (430.000 € for SGA, Role: PI, WP-leader) Collaborations with Univ. Cagliari (IT) (Prof. Paolo La Colla); Gabon Pasteur Institute (Dr. M. Karjanji  ); Gottingen Primate Centre (Prof. Hunsman & Dr. C. Stahl) Denmark University (Prof. Erik  Pederson), etc.
  • INTEREG III  program, “Development nanostructured of anti-bacterial surfaces” 2006-2008 (120.000 € for SGA) (Role: partner). Collaboration with the groups of Prof. Missirlis (Mechanical Emgineering; UPAT), Prof. I Spiliopoulou (Microbiology, Medical School), and Prof. Mataras (Chemical Engineering, UPAT)
  • Industry-funded projects (2007, 2014-) (> 70.000 € ; Role: Coordinator)
  • FP7/ Large scale program Nanotechnology-Materials-Processes, “Nanoparticles for therapy and Diagnosis of Alzheimer’s disease (NAD)” No. 212043 (870.000€ for SGA;  2008-2013, Role: PI, WP-leader). Collaborations with Prof. M. Masserini &Prof. F. Nicotra (Milano Bicocca Univ, IT), Dr. Mario Salmona (Mario Negri Institute, IT); Prof. P. Couvreur & Karine Andrieux (Univ Paris-Sud, FR); Nanovector (IT); Stab Vida (PT), Guerbet (FR), etc.
  • Industry funded projects 2015, 2016, 2017 (~20.000 €).
  • Erasmus Mundus Joint Master Degree –NANOMED (Nanomedicines for Drug Delivery)  2017-2022 (Collaboration with Universities of  Paris Descartes (FR), Angers (FR), Pavia (IT)); 130.000 € for UPAT. Academic Coordinators for UPAT: SGA and Prof. P. Klepetsanis.
  • RIS 3 Specialization Program in MicroElectronic and Materials (Achaia Municipality, GR) “Development of novel nanocarriers for long acting insulin-like peptides (Nano-INS), Starting 2018, 80.000€ for SGA. Role: Partner (PI for UPAT); Collaboration with CBL Biopharmaceuticals, Prof. Kleomenis Barlos.
  • EDVM-34 (Ministry of Education, GR) “Innovative Systems for Delivery of anti-cancer drugs and imaging agents (SISTOFAR)”, 2018-2020,  58.000€ for SGA (Coordinator).
  • EREYNO_KAINTOMO (2018-2021). “Preclinical development of INNOvative FORmulations of antibiotics for intraocular administration for the treatment / prevention of postoperative endophthalmIitis “INNO-FOR-I249.000 € for SGA, Coordinator; Collaboration with University of Crete (Prof. Mil. Tsilibaris, Prof. E. Scoulika) and COOPER Pharmaceuticals.
  • EREYNO_KAINTOMO (2018-2021).  “Development of Innovative Neuroprotective Neurogenerative Synthetic Micro-Neurotrophins”. 100000€ for SGA, Partner (PI for ICEHT/FORTH); Collaboration with University of Crete (Prof. Achilleas Gravanis & Prof. I. Charalampopoulos); FORTH-IMBB (Dr. N. Krestovali); NRI (Dr. Theodora Calogeropoulou); Qualia Pharmaceuticas; BioNature.
  • EREYNO_KAINTOMO (2018-2021). “NOVEL LIPOSOMAL AND POLYMERIC NANOPARTICLES FOR CONTROLLED TRANSPORT AND RELEASE OF DOXORUBICIN AGAINST TRIPLE NEGATIVE BREAST CANCER (lipodox)”. 75000€ for SGA, Partner (PI for ICEHT/FORTH); Collaboration with University of Athens (Dept. Chemistry); University of Thessaly (Medical School); DEMO.
  • EDVM-103 (Ministry of Education, GR) Innovative NanoSystems against Staphylococcal biomembranes (NANO STAR)”, starting 2020. 55.000€ for SGA (Coordinator together with Prof. I Spiliopoulou, Microbiology, Medical School, UPAT).
  • Smart Bone Regeneration (SBR). H2020-SC1-2019-Single-Stage-RTD, RIA, 874896. Starting 01-01-2020 – 31-12-2024; Role: PI for Dept. of Pharmacy, Co-Coordinator with Prof. Elias Panagiotopoulos (Medical School, UPAT). 780000 € for UPAT; 409318€ for SGA. Collaboration with 9 groups (Industrial and Academic from Europe).
Teaching Activities
 For the Teaching in the Dept. of Pharmacy:
 (1989-) Undergraduate Program (Pharmacy Dept):
  1. (1989-2006) Pharmaceutical Technology III (renamed as Biopharmaceutics and Pharmacokinetics from 2002) [Textbook (in Greek)]
  2. (2006-)  Pharmaceutical Technology I, Pre–Formulation/Design; Biopharmaceutical basis for formulation development. [Textbook (in Greek)]
  3. (1989- ) Pharmaceutical Technology II - Preparation of Drug Formulations. Course [Textbook (in Greek)] and Series of Laboratory Practical’s [Lab book (in Greek)] on Formulation Development and Quality Control Testing.

(1995-) Postgraduate Program (Pharmacy Dept):

  1. (1995 – 2006) Applied Pharmacokinetics,
  2. (1995-) A series of Postgraduate courses on Pharmaceutical Technology; Innovative NanoFornulations, Advanced Drug Delivery Systems, Liposome Technology, etc. (depending on the specific needs of the postgraduate program of the Department of Pharmacy)
(1997-2008) For the Socrates/Erasmus Intensive Program/Workshop on: “Novel Drug Delivery Systems”
(1997-98, 1999-2000 & 2008): Liposome Technology and Applications in Therapeutics. Lecture on Liposomal systems for Drug delivery and Targeting.
(2017- ) EMJMD NANOMED: Lectures in Preformulation; Pharmaceutical Technology, Classical and Innovative Formulations; Nanomedicines
 1981: Scholarships from Greek State Scholarships’ Foundation (IKY) for outstanding performance during first year of undergraduate studies (Ranking in top 5% of class)
 1982: Scholarships from Greek State Scholarships’ Foundation (IKY) for outstanding performance during second year of undergraduate studies (Ranking in top 5% of class)
 1983: Scholarships from Greek State Scholarships’ Foundation (IKY) for outstanding performance during third year of undergraduate studies (Ranking in top 5% of class)
 1984: Honor of reading the scientific oath, during the graduation ceremony, as the highest scoring student of the period.
 1988-89: Research Fellowship, from University of South California (from NIH grant), L.A, USA.
 1990: Invited to participate in the Socrates Inter-University Network on Advanced Drug Delivery Systems, by the Coordinator Prof. Rogerio Gaspar (University of Coimbra, PT).
 1992-93: Research Fellowship, University of London (from MOD funded project), London, UK.
 1993: Grant for participation as invited speaker in NATO ASI: "Targeting of Drugs: Advances in System Constructs", Sounio, Greece (1993).
 2003: Invited to participate as a partner and WP leader, in the research proposal SHIVA (EU-FP6), and suggested by the reviewers as the co-coordinator of the project.
 2006: Invited (by Coordinator) to participate in the Marie Curie Network Galenos and the proposal “Euro PhD on Advanced Drug Delivery Systems” as a partner and Host Organization for three PhD students.
 2008: Invited (by Coordinator) to participate as a partner and WP-leader in the research proposal NAD (EU-FP7), as the Laboratory for development of liposomal formulations to target the brain (for Alzheimer’s disease).
 2008-2016: 3 Poster or short oral talk prizes in Panhellenic Pharmaceutical Congresses, for young researchers of my group (two for E. Markoutsa and one for K. Papadia).
2008: Guest Editor for Special Issue: “Nanomedicines” J. Biomedical Nanotechnology, Vol 4.
 2011: EuroNanoForum Budapest. Best poster award to PI’s student, A. Skouras, http://www.
2012-: Member of the Jury Committee (one of the 70 honorable members) for the Maurice-Marie Janot Honorary Award and Lecture.
 2014: Short-oral-communication prize for Post-Doc, Dr. S. Mourtas. (Prize: 1000 ILS) at the Israel-Greece Joint Meeting on Nanotechnology BioNanoscience, 20-23.10.2014, Weizmann Institute, Israel.
 2016: Invitation (by the group of partners) to be a partner and Coordinator in the research proposal FUSION (submitted as FET open project/H2020, but not funded), which was transformed into the proposal Smart Bone Regeneration (SBR), that has been funded in 2019.
 2017: Invitation as member of the Advisory Board of the School of Pharmacy, University of Catania (IT).
 2018: Invitation to Chair Session "WS-2" in ICONAN Conference, Rome, IT, 2018
 2018: Guest Editor for the Special Issue: «Liposomes as Drug Carriers» in Molecules (10-1-2018)
 2019: Guest Editor for Special Issue: “Overcoming Drug Delivery Problems through Advanced Drug Delivery System Design” in Pharmaceutics (2019-20).
 2019: Invitation to join the faculty of the PhD Program of Experimental Medicine at University of Pavia.
Conference Organization
President of Organizing Committee:
 President of Organizing Committee for Erasmus 10-day Workshops on Liposome Technology (1997)
 President of Organizing Committee for Erasmus 10-day Workshops on Liposome Technology (1998)
 President of Organizing Committee for Erasmus 10-day Workshops on Liposome Technology (2000)
 President of Organizing Committee of International Workshop on Nanomedicines: Nanoparticulates for Drug Delivery”, September 11-22, Patras, Greece, (2008)
 President of Organizing Committee of the 2nd Panhellenic Pharmaceutical Sciences Conference, September (2014), Patras, Greece
 President of Organizing Committee for 2nd International Workshop on Nanomedicines, EMJMD NANOMED, Patras. July (2019)
Member of Organizing Committee:
  1. International Conference on Drug Delivery for the third Millenium, Pisa, Italy, 10-12 Oct, 1999;
  2. (ii)   2nd Mediterranean Meeting of the CRS- local Chapters «New perspectives in Controlled Release», Athens, 2001;
  3. (iii) 1st International Symposium on Plasma Proccesing and Biomedical Applications- ISPRBA-1”, 27-20 September, Milos, Greece, 2008;
  4. (iv) Iasted Conference on Nanotechnology and Applications-NANA 2008, 29/9 – 1/10, Crete, Greece, 2008 (regional committee)
  5. (v)   5th International BBBB conference, Sept 26-28, 2013, Athens, GR .
  6. (vi) 2nd International Congress of CRS-Greek Local Chapter, 22-24 June 2016, Athens GR
Scientific Committees:
Scientific Committee member for International Conference of European Association of Pharma Biotechnology [EAPB], Trieste, 2004
 -Advisory board Pharma BioTec Europe Symposium of Pharmaceutical Biotechnology 25. – 28. April 2004 , Trieste
 -Publicity Committee member (invitation by Conference Chair) of 3rd Skin and Formulation Symposium, March 9-10, Versailles, France, 2009
 Member of Scientific Committee in all the Panhellenic Pharmaceutical Conferences (organized by: i. Panhellenic Pharmaceutical Society; ii. Pharmaceutical Society of Thessaloniki [Conferences of Applied Pharmacy], iii. The three Pharmacy Dept. in Greece [Conferences of Pharmaceutical Sciences], from 2010-to-date, and in many of the Conferences/Seminars organized by students of Pharmacy.
Professional Affiliations
  • Pan-Hellenic Association of Pharmacists
  • APGI/APV (Association de Pharmacie Galenique Industrielle)
  • European Federation of Pharmaceutical Scientists (EUFEPS)
  • AAPS (American Association of Pharm. Scientists)
  • Controlled Release Society (CRS)
  • CRS -Greek Chapter [President 1999-2001]
  • International Liposome Society (ILS)
  • Galenos Network for novel Drug delivery Exploitation and Education
Professional Activities
Editorial activities:
 Editor Europe for the Journal of Biomedical Nanotechnology (2006-2017)
 Editorial Board Member of Journal of Drug Delivery (2010 - )
 Editorial Board Member of Drug Delivery (Hindawi) (2010- )
 Editorial Board Member Bio Med Research International (Hindawi) (2011- )
 Editorial Board Member of Pharmaceutics (MDPI) (2019- )
 Referee for >70 Pharmaceutical and related Scientific journals. (between which: Nature Nanotechnology, J. Contr. Release, Small, ASC-Nano, Biomaterials, Nanomedicines, Advanced Drug Delivery Reviews, Langmuir, Pharmaceutical Research, IJP, EJPS, JPS, Drug Targeting,  J. Lip. Research, etc)
Research Evaluation Activities:
 Research proposal Evaluation for European Commission, Research Directorate, 2003, (FP6)
 Research proposal Evaluation for European Commission, Research Directorate, 2004, (FP6)
 Research proposal Committee member & Raporateur EC, 2004, (FP6)
 Research proposal Evaluation for European Commission, Research Directorate, 2007 (FP7),
 Mid-Term Evaluation of research project for EC-IMI, 2015 (Horizon 2020)
 Evaluator for Spanish Ministry of Development and Research (Evaluatores), (2006 & 2008)
 Evaluator for Dutch Research Foundation, (2006)
 Leukemia Research Organization, UK, (2008)
 Evaluator for British cancer Research foundation (2009)
 Evaluator for TWAS Research Grants Programme (The academy of sciences for the developing world) Trieste, Italy, (2009)
 Evaluator for Norway excellence center, (2014)
 Evaluator for QNRF (Qatar National Research Fund), (2016, 2018)
 Evaluator for Graduate study program, Cyprus Evaluation Directorate, Ministry of Education, 2017
 Evaluator for Israel Research Council, (2017, 2019)
 Evaluator for Austrian Research Foundation, (2019)
Member of Committees (abroad):
Member of Scientific Committee of the International Conference of EAPB (2004).
 Member of Scientific Advisory Board Europe, of New Drugs (official publication of EAPB) (2004).
 Member of the Committee for an Industrial PhD approval, University of Denmark, 2010
 Member of the Advisory Board of the School of Pharmacy of the University of Catania (2017- )
 Member of Promotion Evaluation Committee after invitation of the Scientific Council at King Abdulaziz City for Science and Technology (KACST) (2018)
National Committee activities:
 Evaluator for the National Foundation of Drugs (EOF) for Bioequivalence Studies (2000- )
 President of the Western-Greece Committee for evaluation of Pharmacy Technicians (2006- )
 Member of the second degree Committee for authorization of Drugs of the National Foundation of Drugs (EOF) (2012-)
 Member of the general assembly of ELIDEK (National Foundation for Research Funding) (2018- )
 Member of the working group for Proposal Evaluations of ELIDEK (2019- )
UPAT and FORTH/ICE-HT Committees:
 Member of the Committee for Academic Advancement of Dept of Pharmacy, UPAT (1992-2004)
 Member of the Committee for the Annual Pharmacy Dept. Guide (1992-1997)
 Department Coordinator of the Erasmus + mobility Program (initially Socrates and then Erasmus) for the Dept. of Pharmacy, Univ. of Patras (1998-to-date)
 Member of the Senate, Univ. of Patras (2004-2005)
 Member of the Graduate Studies committee, Dept. of Pharmacy, Univ. of Patras (1998-2018)
 Member of the Ethics Committee, UPAT (2008-2010)
 President of the Internal Evaluation Committee of the Dept. of Pharmacy, UPAT (2012-to-date).
 Seminar Committee, FORTH/ICE-HT (2008-to-date)
  1.  Liposomes containing particulate materials. WO9509610 (A1) Publication date: 1995-04-1 3/US2002041895 - 2002-04-11 Inventor(s): G. Gregoriadis, S.G. Antimisiaris, I. Gursel.
  2. A method for immobilization of bioactive substances on surfaces for improving haemocompatibility.  Greek Patent, 2006, Inventor(s):  S. G. Antimisiaris, I. Missirlis, G. Michanetzis, G. Koromila.
  3. Complex formulations for administration of microbicides or other categories of drugs via mucosal (or vaginal or rectal) routes, with high drug-loading capacity and controllable drug release rates. Greek Patent, 20090100244, 2009, Inventor(s):    S.G.Antimisiaris, P.Klepetsanis, S. Mourtas
  4. Treatment of Prostate tumors with arsonoliposomes, US Provisional Patent, B1021US00, 2010, Inventors: S.G. Antimisiaris, P.V. Ioannou, M. Wei
  5. Novel curcumin derivatives with improved physicochemical properties and surface-decorated Nanoliposomes (with the derivatives) with very high affinity for Amyloid-β1-42 peptide. Greek Patent application 20100100563, 2010, Inventor(s): S.G.Antimisiaris, F. Nicotra, S. Mourtas, C. Zona, B. LaFerla, A. Niaraki
  6. System for Sustained release of drugs which is suitable for administration as an injectable or implant. Greek Patent application 2019, Inventor(s): S.G.Antimisiaris, M.Tsilibaris, S. Blazaki, K. Pachis
Publications (GENERAL)
 108 papers peer-reviewed journals, 10 chapters in books (or series), 282 Abstracts in proceeding of National & International conferences, 1 World patent, 1 PCT application and 4 Greek patents. Participation in > 160 International conferences/workshops;
 Invited speaker in 70 National and International scientific meetings/workshops/conferences.
 (Google Scholar Citations 3483 (all), 2028 (since 2014); h-index: 35 (all), 25 (since 2014); i10-index: 77 (all) , 53 (since 2014); 
 (Scopus) 111 cited documents: Citations: 2741; h-index: 31
Publications (peer reviewed int. journals)
  1. P. Macheras, M. Koupparis, S. G. Antimisiaris, " Effect of Temperature and Fat content on the binding of Hydrochlorothiazide and Chlorothiazide to milk", J Pharm Sci-US, 77, 334-336, (1988).     IF: 2.095
  2. P. Macheras, M. Koupparis, S.G.Antimisiaris, "Effect of Temperature and Fat content on the Solubility of Hydrochlorothiazide and Chlorothiazide in Milk", J Pharm Sci-US, 78, 933-936, (1988)  IF: 2.095
  3. P. Macheras, M. Koupparis, S.G.Antimisiaris"An in-vitro model for exploring CR Theophylline-milk fat  Interactions", Int.J. Pharm., 54, 123-129, (1989).    IF: 1.005
  4. P. Macheras, M.Koupparis, S.G.Antimisiaris, "Drug Binding and Solubility in Milk", Pharm. Research, 8, 537-541, (1990).  IF: 2.475
  5. P. Macheras, C. Reppas, S.G.Antimisiaris, " Binding of drugs in milk : The role of Casein in Milk Protein Binding [letter]", Pharm. Research, 8, 550, (1991).  IF: 2.475
  6. S. G. Antimisiaris, Jayesekera,P., Gregoriadis,G., "Liposomes as vaccine carriers: Incorporation of soluble and particulate antigens in giant vesicles", J. Immunol. Methods, 166, 271-280, (1993).  IF: 2.202
  7. Gursel, I. Antimisiaris, S.; Jayasekera, P.; Gregoriadis, G. “Giant liposomes as potential vesicles for live or attenuated microbial vaccines”, Drug Targeting and Delivery, 6 , 35-50, (1995).  IF: -  )
  8. C.G. Kontoyannis, S.G. Antimisiaris, D. Douroumis, «Simalteneous quantitative determination of diazepam and liposomes using differential pulse polarography, Anal. Chim. Acta, 391, 83-88, 1999. IF: 1.900
  9. C.G. Kontoyannis, S.G. Antimisiaris, D. Douroumis, «Quantitative determination of the non-entrapped chlorothiazide in the presence of liposomes using differential pulse polarography», Talanta, 48, 979-983, 1999.   IF: 1.228
  10. M. Kokona, P. Kallinteri, D. Fatouros, S. G. Antimisiaris*, «Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: Effect of lipid composition . Eur. J. Pharm. Sciences, 9, 245-252, 2000. IF: 2.436
  11. Antimisiaris, S.G,  Siablis, Liatsikos, E., Kalogeropoulou, C., Tsotas, V, Tsota E, Karnabatidis, Fatouros D.G., Barbalias, «Preparation and in-vitro evaluation of liposome covered stents for use as ureteral stents», J. Endourology, 14:9, 743-747, 2000.  IF: 1.227 –
  12. E. Papadimitriou and S.G. Antimisiaris*, «Interactions of PC/Chol and PS/Chol liposomes with human cells in vitro», J. Drug Targeting, 8:5, 335-351 2000.  IF: 1.528
  13. D. Fatouros, S.G. Antimisiaris*, «Physicochemical properties  of liposomes incorporating hydrochlorothiazide and chlorothiazide», J. Drug Targeting, 9:1, 61-74, 2001   IF: 2.045
  14. P. Kallinteri, W-Y. Liao, S.G. Antimisiaris* and K.H.L. Hwang, «Characterization, Stability and in-vivo distribution of Fetuin F2 glycopeptide incorporating DSPC/Chol liposomes prepared by mild cholate incubation, J.Drug Targeting, 9:2, 155-168, 2001.  IF: 2.045
  15. D. Fatouros, O. Gortzi, P. Klepetsanis, S.G. Antimisiaris*, M.C. Stuart, A. Brisson, P. V, Ioannou, «Preparation and properties of arsonolipid containing liposomes», Chem. Phys. Lipids, 109, 75-89, 2001. IF: 2.906
  16. Fatouros, K. Haztidimitriou, S.G. Antimisiaris*, «Liposomes encapsulating prednisolone and prednisolone-cyclodextrin complexes: comparison of membrane integrity and drug release», Eur. J. Pharm. Sciences, 13, 287-296, 2001.    IF: 2.436
  17. Paraskevi Kallinteri, Sophia G. Antimisiaris*, ‘Solubility of drugs in the presence of gelatin: effect of drug lipophilicity and degree of ionization», Int. J. Pharm., 221, 219-226, 2001.   IF: 1.495
  18. Gortzi, P. Klepetsanis, S.G. Antimisiaris*, P. V. Ioannou, «Capability of arsonolipids to transport divalent cations: A pressman cell study », Chem. Phys. Lipids, 112, 21-29, 2001.  IF: 2.906
  19. Paraskevi Kallinteri, Euangelia Papadimitriou, Sophia G. Antimisiaris*, «Targeting of small unilamellar liposomes bearing asialofetuin glycopeptide conjugates to HepG2 cells», J. Liposome. Res., 11(2&3), 175-193, 2001.  IF: 1.430
  20. Olga Gortzi, Evangelia Papadimitriou, Christos G. Kontoyannis, Sophia G. Antimisiaris* and Panayiotis Ioannou, «Arsonoliposomes, a novel class of arsenic containing liposomes: Effect of palmitoyl-arsonolipid containing liposomes on the viability of various cancer and normal  cells in culture», Pharm. Research, 19:1, 79-86, 2002.   IF: 2.609
  21. Dimitris Fatouros, S.G.Antimisiaris*. «Effect of Amphiphilic drugs on the Stability and Zeta-Potential of their liposome formulations: A study with Prednisolone, Diazepam and Griseofulvin», J. Coll. Inter. Scienc., 251, 271-277, 2002.  IF: 1.864
  22. P. Kallinteri, S.G.Antimisiaris*, I. Tsota, C. Kalogeropoulou, D. Karnabatidis, D. Siablis, «Dexamethasone incorporating liposomes: An in vitro study of their applicability as a slow release delivery system of dexamethasone from covered metallic stents», Biomaterials, 23, 4819-4826, 2002.  IF: 3.008
  23. Katharios Pantelis, Antimisiaris Sophia, Pavlidis Michalis & Iliopoulou-Georgudaki Joan, «Serum pharmacokinetics of ivermectin in sea bream, sparus aurata using a direct competitive elisa.» Fish Physiol Biochem 26 (2): 189-195, 2003.  IF: 0.778
  24. Olga Gortzi, Evangelia Papadimitriou, Sophia G. Antimisiaris* and Panagiotis Ioannou, «Cytotoxicity of arsonolipid containing liposomes towards cancer and normal  cells in culture: Effect of arsonolipid acyl chain length», Eur. J. Pharm. Sciences, 18, 2, 175-183, 2003.  IF: 2.248
  25. Sophia G. Antimisiaris*, Panayiotis V. Ioannou, Philippe M. Loiseau   «In vitro antileishmanial and trypanocidal activities of arsonoliposomes and preliminary in vivo distributionJ. Pharmacy and Pharmacology, 55 (5): 647-652,, 2003  IF: 1.502
  26. Katharios P., Iliopoulou-Georgudaki J., Antimisiaris S., Verri T., Toma P., Acierno R., and Maffia M. Pharmacokinetics of cephalexin in sea bream, Sparus aurata (L.) after a single intraperitoneal injection. Journal of Applied Ichthyology. J Appl Ichthyol. 20 (5): 422-426 OCT 2004  IF: 0.563
  27. P. Kallinteri, D. Fatouros, P. Klepetsanis, S. G. Antimisiaris*, “Arsenic trioxide liposomes.Encapsulation efficiency and in vitro stability, J. Liposome Res., 14 (1-2): 27-38 2004   IF: 1.259
  28. Antimisiaris SG*, Klepetsanis P, Zachariou V, et al. In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice. Int J Pharm 289 (1-2): 151-158 JAN 31 2005   IF: 2.156
  29. Fatouros DG, Piperoudi S, Gortzi O, Ioannou PV, Antimisiaris SG.*. Physical stability of sonicated arsonoliposomes: Effect of calcium ions. J Pharm Sci-US 94 (1): 46-55 JAN 2005    IF: 2.237
  30. Fatouros DG, Klepetsanis P, Ioannou PV, Antimisiaris SG. The effect of pH on the electrophoretic behaviour of a new class of liposomes: arsonoliposomes. Int J Pharm 288 (1): 151-156 , 2005   IF: 2.156
  31. Fatouros DG, Bouropoulos N, Ioannou PV, Antimisiaris SG. Stability and aggregation studies of non-sonicated arsonolipid-containing vesicles, Cell Mol Biol Lett 10 (1): 173-183 2005  IF: 0.829
  32. S.Piperoudi, P.V.Ioannou, P.Frederik, S.G.Antimisiaris*, Arsonoliposomes: Effect of lipid composition on their stability. J Liposome Res 15 (3-4): 187-197 2005  IF: 1.000
  33. Sophia Piperoudi, Dimitris Fatouros, &, Panayiotis V. Ioannou, Peter Frederik, Sophia G. Antimisiaris,*, Incorporation of PEG-lipids in arsonoliposomes can produce highly stable arsenic-containing vesicles of specific lipid composition. Chem. Phys. Lipids 139:2, 96-106, 2006. IF: 2.371
  34. G. Koromila, G. Michanetzis, Y.F. Missirlis, and S.G.Antimisiaris*, Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: Effect on haemocompatibility, Biomaterials, 27:12, 2525-2533, 2006.  IF: 5.196)
  35. S. Koutsopoulos, DG. Fatouros, PV. Ioannou, SG Antimιsiaris. Thermal behaviour of non-sonicated arsonolipid Dispersions. Biophysical Chemistry, 121:2, 150-54, 2006   IF: 1.784
  36. D.Fatouros ,PV Ioannou, SG Antimisiaris*Novel Nanosized Arsenic Containing Vesicles For Drug Delivery: Arsonoliposomes. (Invited Review article) J. Nanoscience & Nanotechnology, 6: 2618-2687, 2006  IF: 2.194
  37. M. Haikou, P. Zagana, PV, Ioannou and SG. Antimisiaris*. Arsonoliposome Interaction with thiols. Effect of pegylation and arsonolipid content on their integrity during incubation in the presence of glutathione. J. Nanoscience & Nanotechnology,  6: 2974-2978, 2006  IF: 2.194
  38. S.G.Antimisiaris*, G. Koromila, G. Michanetzis, Y.F. Missirlis, Liposome coated stents: A method to deliver drugs to the site of action and improve stent blood-compatibility. (Invited paper) Journal of Liposome Research, Volume 16, Number 3, 303-309, 2006  IF: 1.037
  39. V. Ntimenou, S. Mourtas, E. Christodoulakis, M. Tsilimbaris, S.G. Antimsiaris*. Stability of protein encapsulating DRV liposomes after freeze drying: A study with BSA and t-PA. Journal of Liposome Research, Volume 16, Number 4, 403-416, 2006 IF: 1.037
  40. P. Hatzi, S. Mourtas, P. Klepetsanis, S.G Antimisiaris*. Integrity of liposomes in presence of cyclodextrins. Effect of liposome type and lipid composition, Int. J. Pharm ,333 (1-2), pp. 167-176, 2007.
  41. S. Mourtas, S. Fotopoulou, (..) Tsakiroglou, S.G. Antimisiaris*.. Liposomal drugs dispersed in Hydrogels. Effect of liposome, drug and gel properties on drug release kinetics. Coll & Surf B: Biointerfaces, 55, 2007.
  42. VA Tsotas, S Mourtas and SG. Antimisiaris* Dexamethasone incorporating liposomes: Effect of lipid composition on drug trapping efficiency and vesicle stability. Drug Delivery, 14(7), 441-445, 2007
  43. M. Zaru, S. Mourtas, P. Klepetsanis, A.M. Fadda and S.G.Antimisiaris*, Liposomes for drug delivery to the lungs after nebulization. Eur. J. Pharmac & Biopharmac, 67 (3), 655-666, 2007
  44. SG. Antimisiaris*, Commentary. J Biomedical Nanotechnology, 3(3), 297-299, 2007
  45. P Zagana, P Klepetsanis, PV. Ioannou, PM. Loiseau, S.G. Antimisiaris* «Trypanocidal activity of arsonoliposomes: Effect of vesicle lipid composition», Biomedicine & Pharmacotherapy, 61, 499-504,2007
  46. P. Zagana, M. Haikou, P. Klepetsanis, E. Giannopoulou, P.V. Ioannou, S.G. Antimisiaris, In vivo distribution of arsonoliposomes: Effect of vesicle lipid compositionInt. J. Pharm, 347 (1-2), 86-92, 2008
  47. S.G.Antimisiaris*, Arsonoliposomes for Drug Delivery, J. Drug Del Scienc & Techn 17, 377-388, 2007  
  48. S. Mourtas, (..), S.G. Antimisiaris*. Integrity of liposomes in presence of various formulation additives, in aqueous dispersions and in hydrogels, Colloids and Surf  B: Biointerfaces, 61 (2), 270-276,  2008
  49. MLManca , (..), AM Fadda, S G.Antimisiaris*, PLGA, Chitosan or Chitosan-coated PLGA Microparticles for Alveolar Delivery? Colloids and Surf B: Biointerfaces, 62 (2), 220-231, 2008
  50. S Mourtas, M Haikou, M Theodoropoulou, C Tsakiroglou, S G. Antimisiaris*, How liposome type, composition and loading influence rheological properties of a liposomal gel. J. Colloid & Inter. Scienc B: 317, 611, 2008
  51. C. Peptu, M. Popa, S.G. Antimisiaris*, Release of Liposome-Encapsulated Calcein from Liposome Entrapping Gelatin-Carboxymethylcellulose Films: J. Nanoscience & Nanotechnology, 8, 2249–2258, 2008   
  52. P. Zagana, M. Haikou, (..) P.V. Ioannou, S.G. Antimisiaris*, Arsonoliposome Interaction with cells in culture. Effect of pegylation and lipid composition. Invited contribution, J. Mol. Nutr. Food Res. 53, 592 – 599, 2009
  53. MLetizia Manca, G Loy, M Zaru, AM Fadda, SG. Antimisiaris* Release of Rifampicin from Chitosan, PLGA and Chitosan-coated PLGA microparticles, Colloids and Surf B: Biointerfaces, 67, 166-170, 2008
  54. S G. Antimisiaris, Guest Editor. A Special Issue on Nanomedicines, J. Biomed. Nanotechnol. 4, 217, 2008
  55. P.A.K. Michanetzis, YF. Missirlis, SG. Antimisiaris* Haemocompatibility of Nanosized Drug Delivery Systems: Has It Been Adequately Considered?  J. Biomed. Nanotechnol. 4, 218-233, 2008
  56. MZaru, ML Manca, AM Fadda SG. Antimisiaris* «Chitosan-coated liposomes for delivery to lungs by nebulization». Colloids& Surf B: Biointerfaces 71 (1), 88-95 , 2009 [IF=4.15]
  57. S. Mourtas, C. Aggelopoulos, P. Klepetsanis, C. Tsakiroglou, S.G. Antimisiaris*, “Complex gel formulations for topical drug administration”, Langmuir, 25 (15), pp. 8480-8488, 2009 [IF=4.45]
  58. S. Mourtas*, (..) S.G Antimisiaris. Haemolytic activity of lipidic carriers: Effect of vesicle size, lipid concentration and PEG-lipid or arsonolipid incorporation. J Biomed Nanotechn. 5, 409-415, 2009[IF=5.25]
  59. Antimisiaris, S.G.  Arsonoliposomes for drug delivery applications, Clinical Lipidology 4 (5), 663-675, 2009
  60. Favretto, M.E., Marouf, S., Ioannou, P., Antimisiaris, S.G., Parker, T.L. Kallinteri, P.  Arsonoliposomes for the potential treatment of medulloblastoma, Pharm. Research 26 (10), 2237-2246  2009 [IF=4.25]
  61. S.G.Antimisiaris, “Preparation of DRV liposomes”, Methods in molecular biology (2010), 605, 51-75.
  62. S.G.Antimisiaris*, P.V. Ioannou, “Arsonoliposomes: preparation and physicochemical characterization”, Methods in molecular biology (2010), 605, 147-62.
  63. G. Besson, (.), S. Antimisiaris M. Kazanji “Protective properties of NRTI (MC1220) incorporated into liposome against Rhesus Macaques with RT SHIV”,  Virology 405 (1), 225-233,  2010 [IF=3.35]
  64. E Markoutsa, G Pampalakis, A Niarakis, (..), S. G. Antimisiaris*, Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line, EJPB,  77: 2, 265-274, 2011[IF=4.25]
  65. S. Mourtas, M. Canovi, (..) , M. Gobbi, S. G. Antimisiaris*,  Curcumin-decorated nanoliposomes with very high affinity for amyloid-b1-42 peptide, Biomaterials, 32: 6, 1635-1645, 2011[IF=7.62]
  66. S. Mourtas, M. Kastellorizios,(..), S. Antimisiaris*. Immobilization of liposomes on Plasma-treated stainless steel surfaces, by covalent binding. Colloids& Surf B: Biointerfaces, 84 (1), 214-220, 2011[IF=4.15]
  67. Canovi, M., Markoutsa, (..), Antimisiaris, S.G* The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials 32 (23), 5489-5497, 2011 [IF=7.62]
  68. Stolte-Leeb N, Loddo R, Antimisiaris S, (..), Stahl-Hennig C Topical NRTI MC 1220 Partially Prevents Vaginal RT-SHIV Infection of Macaques. AIDS Res Hum Retroviruses. 27,933-943, 2011. [IF=2.72]
  69. M-T Popescu, S Mourtas, G Pampalakis, S G. Antimisiaris, C Tsitsilianis. pH-Responsive Hydrogel/Liposome Soft Nanocomposites For Tuning Drug Release, Biomacromolecules, 12 (8) , 3023-3030, 2011. [IF=5.75]
  70. S. Mourtas, P. Klepetsanis, (…),S.G. Antimisiaris*. Liposomal gels for vaginal delivery of the microbicide MC1220: Preparation and in vivo vaginal toxicity and pharmacokinetics, .NanoLife 1, 3-4(2010) 195-205
  71. A.Skouras, S. Mourtas, (..), SG. Antimisiaris*. USPIO encapsulating nanoliposomes with high entrapping efficiency, stability and magnetic properties. Nanomedicine: NBM 7 (5), 572-579, 2011[IF=6.69]
  72. M. Taylor, (..) S G Antimisiaris, D. Allsop. Effect of curcumin-associated & lipid ligand functionalised liposomes on aggregation of the Alzheimer's Aβ peptide. Nanomedicine: NBM (5), 541-550, 2011. [IF=6.69]
  73. E. Markoutsa, K. Papadia, (..), S.G. Antimisiaris*. Anti-Aβ MAb and dually-decorated nanoliposomes, European Journal of Pharmaceutics and Biopharmaceutics 81 (1) , pp. 49-56, 2012. [IF=4.25]
  74. M. Kastellorizios, (..), S. G. Antimisiaris*. Improving the haemocompatibility of metallic surfaces by covalent binding of heparin-encapsulating functionalized liposomes. Int J Pharm 432 (1-2) . 91-98, 2012. [IF=3.55]
  75. V Ntimenou, A Fahr, S G. Antimisiaris*  Elastic Vesicles for Transdermal Drug Delivery of Hydrophilic Drugs: J. Biomed. Nanotechnol. 8, 613-623, 2012. [IF=7.57]
  76. Svarnas, P, Matrali, SH., (..), Clément, F., Antimisiaris, S.G* Atmospheric-pressure guided streamers for liposomal membrane disruption. Applied Physics Letters 101 (26) , art. no. 264103, 2012. [IF=3.79]
  77. A Lazar, S Mourtas, (..), SG Antimisiaris, Charles Duyckaerts. Curcumin-conjugated nanoliposomes with high affinity for Aâ deposits: possible applications to AD Nanomedicine: NBM, 9 712-721, 2013. [IF=6.69]
  78. K Papadia, E Markoutsa, S.G. Antimisiaris*. A Simplified Method to Attach Antibodies on Liposomes. J. Biomed. Nanotechnol. 10, 871-876, 2014. [IF=7.57]
  79. Antimisiaris, S.G. Potential of nanoliposomes for the therapy and/or diagnosis of Alzheimer's disease: Recent progress, Clinical Lipidology, Volume 9, Issue 5, 477-481, 2014 [IF=0.87]
  80. E. Markoutsa, K. Papadia, (..), G.T. Stathopoulos, S.G. Antimisiaris* Mono and Dually Decorated Nanoliposomes for Brain Targeting, In Vitro and In Vivo, Pharm Research, 31, 5, 1275-1289, 2014 [IF=3.42]
  81. S Mourtas, (..), SG. Antimisiaris*. Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for AD, Eur J Med Chem, 80, 175-183, 2014 [IF=3.45]
  82. C Airoldi, S Mourtas, et al. Copper-free click decorated liposomes with glycol-ligand display binding affinity and aggregation inhibition ability towards amyloid-β peptide, Eur J of Med Chem. 85, 43-50, 2014 [IF=3.45]
  83. H. Matloob, S. Mourtas, P. Klepetsanis, S. G. Antimisiaris*, Increasing the stability of curcumin in serum with liposomes or hybrid drug-in-cyclodextrin-in-liposome systems, Int J Pharm 476, 1–2, 108, 2014 [IF=3.65]
  84. P Svarnas, (..), S G. Antimisiaris*. Assessment of Atmospheric-Pressure Guided Streamer Influence on Liposomes with Different Composition, (plus Cover Picture) Plasma Process. Polym  2015 [IF=3.73]
  85. Antimisiaris, S.G*, Mourtas, S. Recent advances on anti-HIV vaginal delivery systems development, Advanced Drug Delivery Reviews, 92 (2015) 123–145 [IF=15.040]
  86. E Markoutsa, (..), SG Antimisiaris*, Comparison of Ligand Decorated liposomes for Inhibition of Amyloid Aggregation and Reverse Amyloid Cytotoxicity. Curr Top Med Chem 15 (22), 2267-2276, 2015 [IF=3.45]
  87. S Mourtas, G Diamanti, (..), SG Antimisiaris*. Inhibition of Bacterial Attachment on Surfaces by Immobilization of Tobramycin-Loaded Liposomes, J Biomed Nanotechn 11 (12), 2186-2196, 2015  [IF=5.35]
  88. K. Papadia, E. Markoutsa, S.G. Antimisiaris*. How do the physicochemical properties of nanoliposomes affect their interactions with the hCMEC/D3 cellular model of the BBB? Int. J. Pharm 509, 431, 2016 [IF=3.994]
  89. K. Terzi, (..), S. Antimisiaris, C.D. Tsakiroglou. Mobility of zero valent iron nanoparticles and liposomes in porous media. Colloids and Surfaces A: Physicochem. Eng. Aspects 506 (2016) 711–722 [IF=2.108]
  90. Antimisiaris, S.G. Preparation of DRV liposomes. Methods in Molecular Biology, 1522, 23-47 2017
  91. Aloisio, C., Antimisiaris, S.G., Longhi, M.R. Liposomes containing cyclodextrins or meglumine to solubilize and improve the bioavailability of poorly soluble drugs. J Mol. Liquids, 229:106-113 2017 [IF=2.740]
  92. K. Papadia., E.Markoutsa.(..), G.T. Stathopoulos, S. G. Antimisiaris*, Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. Eur. J. Pharm. Sciences, 101:140-148, 2017. [IF=3.773]
  93. S. Antimisiaris*, S. Mourtas, K. Papadia, Targeted si-RNA with liposomes and exosomes (extracellular vesicles): How to unlock the potential. Int. J. Pharm, 525, 293–312; 2017. [IF=3.994]
  94.  K. Papadia, (..), G. T. Stathopoulos, S. G. Antimisiaris*. Multifunctional LUV liposomes decorated for BBB and amyloid targeting - B. Eur. J. Pharm. Sciences 102, 180-187; 2017 [IF=3.773]
  95. T. Αgalioti, (..), S. G. Antimisiaris, (..), A. Μarazioti, and G.T. Stathopoulos. Mutant KRAS promotes malignant pleural effusion formation. Nature Communications, 8, 15205, 2017. [IF=11.329]
  96. M. Agrawal, (..) S.G. Antimisiaris, S. Mourtas, A. Alexander. Recent advancements in liposomes targeting strategies to cross BBB for treatment of AD. Journal of Controlled Release 260, 61–77; 2017 [IF=7.441]
  97. Svarnas, P., (..) Antimisiaris, S.G. Liposomal membrane disruption by means of miniaturized dielectric-barrier discharge in air: Liposome characterization. Journal of Physics D: Applied Physics 50(34),345403; 2017 [IF=2.373]
  98. Pachis, K., (..),Klepetsanis, P.,(..)Antimisiaris, S.G. Sustained release of intravitreal flurbiprofen from a novel drug-in-liposome-in-hydrogel formulation Eur J Pharm Sciences 109, 324-333; 2017 [IF=3.773]
  99. Agrawal, M,(..), Antimisiaris, S.G, (..), Alexander, A.  Nose-to-brain drug delivery: Update on clinical challenges & progress towards approval of anti-Alzheimer drugs. J Control Rel 281, 139-177; 2018 [IF=7.441]
  100. Agrawal, M., (..), Antimisiaris, S.G., Alexander, A. Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opinion on Drug Delivery 15(6), 589-617, 2018 [IF=5.553]
  101. Antimisiaris, S., Mourtas, S., Papadia, K. Brain targeting with lipidic nanocarriers (  Book Chapter) Design of Nanostructures for Versatile Therapeutic Applications pp. 255-324 2018.
  102. Trapani, A, (..),Antimisiaris,S.G. Protection of dopamine towards autoxidation by encapsulation in chitosan- or thiolated chitosan-coated-liposomes. Coll & Surf B: Biointerfaces 170 11-19, 2018 [IF=3.997]
  103. Skouras, A, Papadia, K., Mourtas, S., Klepetsanis, P., Antimisiaris, S.G. Multifunctional doxorubicin-loaded magnetoliposomes with active and magnetic targeting properties. Eur J Pharm Sciences 123, 162-172, 2018 [IF=3.773]
  104. Antimisiaris, S.G., Mourtas, S., Marazioti, A. Exosomes and exosome-inspired vesicles for targeted drug delivery Pharmaceutics 10(4),218 2018 [IF= 3.746]
  105. Michanetzis GPA, Markoutsa E, Mourtas S, (..) Antimisiaris SG., Hemocompatibility of amyloid and/or brain targeted liposomes, Future Medicinal Chem, 11(7), pp. 693-705 2019 [IF= 3.556]
  106. Mourtas, S., Christodoulou, P., Klepetsanis, P., (...), Barlos, K., Antimisiaris, S.G. Preparation of benzothiazolyl-decorated nanoliposomes. Molecules 24(8),1540; 2019 [IF= 3.060]
  107. Marazioti, A., Papadia, K., Giannou, A., Stathopoulos, G.T., Antimisiaris, S.G. Prolonged retention of liposomes in the pleural cavity of normal mice and high tumor distribution in mice with malignant pleural effusion, after intrapleural injection International Journal of Nanomedicine14, pp. 3773-3784  2019 [IF 4.54]
  108. Marazioti, A., Papadia, K., Kannavou, M., (...), Stathopoulos, G.T., Antimisiaris, S.G. Cellular vesicles: New insights in engineering methods, interaction with cells and potential for brain targeting. Journal of Pharmacology and Experimental Therapeutics, 370(3), pp. 772-785 2019 [IF 3.830]
  109. Blazaki S, Pachis K, Tzatzarakis M, Tsilimbaris M, Antimisiaris S.G. Novel Liposome Aggregate Platform (LAP) system for sustained retention of drugs in the posterior ocular segment following intravitreal injection. Int. J Pharm under publication 2019 [IF 4.270]
 G. Gregoriadis, I. Gursel and S. G. Antimisiaris, "Microbe entrapment in giant Liposomes", In : Nonmedical Applications of Liposomes (eds. L. Lasic and Y. Barenholz) CRC-Press, Boca Raton,  pg. 263-269, 1996
 S. G. Antimisiaris*, D. Fatouros and P. Kallinteri. Invited Chapter on Liposome Technology, for the Pharmaceutical Manufacturing Handbook, Section 5: New Dosage Forms, Chapter 5.3, Eds. John Wiley and Sons, pp. 443-533, 2008
 S. G. Antimisiaris*. Lipid based nanoparticles for Drug Delivery. Invited chapter for Encyclopedia of Nanoscience and Nanotechnology, 2010
 S.G.Antimisiaris, “Preparation of DRV liposomes”, Methods in molecular biology (2010), 605, 51-75.
 S.G.Antimisiaris*, P.V. Ioannou, “Arsonoliposomes: preparation and physicochemical characterization”, Methods in molecular biology (2010), 605, 147-62.
 S.G.Antimisiaris, K.A. Peptu, “Liposomes in Drug Delivery”, In: Systems Medical Applications of Polymers, Edited by Marcel Popa, Raphael M. Ottenbrite, and Constantin V. Uglea, Volume 2: CHAPTER 8, Pages 1–35 (Copyright © 2011 by American Scientific Publishers)
 Antimisiaris, S.G* Mourtas, S., Markoutsa, E., Skouras, A., Papadia, K. Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease (Book Chapter), Advanced Healthcare Materials, Pages 87-179, 2014
 Mourtas, S., Markoutsa, E., Skouras, A., Papadia, K. and S.G. Antimisiaris. Applications of Nanoparticles for AD’s Treatment and Diagnosis, in: Frontiers in Nanomedicine, Edited by Maria Luisa Bondì , Chiara Botto , Erika Amore; Volume 1 161-221, 2015
 Antimisiaris, S.G. Preparation of DRV liposomes. Methods in Molecular Biology, 1522, 23-47 2017
 G. Gregoriadis, I. Gursel and S. G. Antimisiaris, "Microbe entrapment in giant Liposomes", In : Handbook of Nonmedical Applications of Liposomes (eds. L. Lasic and Y. Barenholz) CRC-Press, Boca Raton,  Chapter 19 -8 pages, 2019
Invited presentations
  1. NATO ASI: "Targeting of Drugs: Advances in System Constructs", Sounio, Greece, 1993.
  2. Intensive Program «Liposome Technology and Applications in Therapeutics», July 1997, Patras, Greece. «Stealth Liposomes: An Introduction»
  3. Intensive Program «Liposome Technology and Applications in Therapeutics», July 1997, Sept. 2000, Sept. 2003, Patras, Greece. «Preparation of giant liposomes incorporating sub-micron size particles. Possible Applications»
  4. Cell Culture and Ex-Vivo Models for Drug Delivery Research, March 27, 1998, Saarbrucken, Saarland, Germany; «Liposome-cell Interactions»
  5. «New Forms and New Routes of Administration for Drugs», April 4, 1998, Athens, Greece; «Fate of Colloidal Carriers after Oral Administration»
  6. Nancy University, Department of Pharmacy. Juin 2, 1998; “Liposomes: I. Preparation et caracterisation des liposomes, II. Devenir in vivo des liposomes, Applications”
  7. Nancy University, Department of Pharmacy, Juin 3, 1998. “Liposomes, III. Interactions avec les cellules, IV. Liposomes comme adjuvants immunologiques”
  8. «Drug Delivery for the third Millenium» Conference, Pisa, Italy, 10-12 Oct, 1999; «Stability of liposomal formulations of prednisolone and prednisolone-cyclodextrin complexes»
  9. 2nd Mediterranean Meeting of the CRS- local Chapters «New perspectives in Controlled Release», Athens, 2001; «Liposome covered stents: A simple novel approach for sustained delivery of Dexamethazone at the site of inflammation»
  10. 2nd Mediterranean Meeting of the CRS- local Chapters «New perspectives in Controlled Release», Athens, 2001 “Arsonoliposomes: A novel class of Liposomes with anticancer potential»
  11. Socrates IP on Dermal delivery of drugs. University of Lyon Claude-Bernard I, Department of Pharmacy, September 2004;  “Liposome applications in Transdermal delivery
  12. Socrates IP on Cyclodextrins. University of Lisbon, Department of Pharmacy, September 2005; “Liposomes and Cyclodextrins”
  13. Socrates IP on Cyclodextrins. University of Lisbon, Department of Pharmacy, September 2005 “Liposomes in Drug Delivery”
  14. Socrates IP on Dermal delivery of drugs. University of Lyon Claude-Bernard I, Department of Pharmacy, September 2005“Liposomes”
  15. ILS “Liposome Advances:” Progress in Drug and Vaccine Delivery, 12-16 December, London, 2005.
  16. 6th International conference and Workshop on Cell culture and in vitro Models for drug Absorption and Delivery, Theme day” Impact of Nanobiotechnology on New medicines. Saarbrucken, Germany, March 1-10, 2006. “Arsonoliposomes Revisited
  17. Socrates IP on Dermal delivery of drugs. University of Lyon Claude-Bernard I, Department of Pharmacy, September 2006; “Liposomes and transdermal delivery of drugs: Incorporation in hydrogels”
  18. 1st School of Biomaterials –“Advanced Biomaterials”, Patras, Greece, June 29-30, 2007.
  19. Aegean RetinaX, July 6-8, Rhodes, GR, 2007Controlled release drug delivery systems for intravitreal administration: What can Liposomes do? »
  20. Skin Barrier Function Workshop 16/9– 2/10, Lyon, FR, 2007Liposomes: Are other routes of administration possible? Focus on Oral, Ocular, Pulmonar and Dermal Routes
  21. 2nd Intereg School on Advanced Biomaterials, 12-14 May, Bari, Italy, 2008.  “Liposomes as a system to prepare Controlled Drug Eluting Biomaterials”
  22. Seminars on Optics and Vision, 8-9, June 2008, Herakleio, Crete, GR “Controlled release DDS for Ocular Delivery: Focus on Liposomes
  23. Nano2Life Summer School “Methods in Micro-Nanotechnology and Nanobiotechnology”, (Lecture 2.2-2.3 July 8, 2008) 30/6 – 10/7, Demokritos, Athens, GR, 2008. “Drug Delivery and Targeting Systems- Focus on Liposomes”
  24. 4th International Workshop on Nanomedicines: Nanoparticulates for Drug Delivery”, September 11-22, Patras, Greece, 2008. Organization of event and Lecturer
  25. 6th Euro Fed Lipids Congress (Oils, Fats & Lipids in the third Millenium), Athens, GR, 2008. “Arsonoliposomes: Novel lipid vesicles with potential for targeted delivery of anticancer and antiparasitic drugs
  26. DIMET COURSE “Nanoparticles in Medicine” March 11-13, 2009 Milan, IT, “Liposomes in nanomedicine
  27. 5th International Biotechnology Forum (IBSF5), May 8-9, 2009 Athens, GR “Nanosized liposomes for on site controlled-release of active agents
  28. Int Conference “From Drug Delivery Systems to Drug Release, Dissolution, Bioequivalence and Biowaivers”, May 28-30, 2009, Athens GR “Nanosized liposomes for construction of drug eluting stents
  29. Biotechnology colloquium organized by the Laboratory of General Biology, School of Medicine, “How a Scientific Hypothesis Can Be Translated to Drug Discovery and Development”, University of Patras and Fondation Santé, Patras, June 10, 2009. “Novel Drug Delivery Systems: Achievements and Challenges”
  30. International Congress on New Delivery Systems, Biosimilars, Bioequivalence – Biowaivers: Scientific, Industrial and Regulatory Aspects             2-3/07/2010, Athens, GR “Immunoliposomes for Drug Targeting: Results with OX
  31. Skin Barrier Functions, Lyon, University of Lyon Claude-Bernard I, FR, October 2010. Liposomes for Drug Delivery: Latest developments with elastic liposomes.
  32. Liposome Advances: Progress in Drug and Vaccine Delivery , December 12-15, 2010, London, UK.  Covalently immobilised liposomes for development of controlled release drug eluting surfaces: Potential for blood compatibility
  33. 10th Eurobic, 22-26/6/2010, Thessaloniki, GR “Nano-Immuno-liposomes for Blood-Brain Barrier (BBB) targeting
  34. Conference of ILS on Liposomes Advances, London, Dec 2011, “Nanoliposomes with ability to target abeta peptide species: potential for therapy and/or diagnosis of AD
  35. COST Workshop: Dendrimers as Composites of Advanced Drug Delivery nano-Systems (aDDnSs). Biomedical Applications, Oct. 4-9, 2011, Athens, GR. “Construction of Nano-Immunoliposomes for Amyloid targeting
  36. NANOTECHITALY 2012, Venezia Mestre, Nov. 21-23, 2012. “Nanoliposomes for drug delivery and targeting: Progress in applications for AD and other diseases
  37. 5th International BBBB Conference, Athens, GR Sept. 2013Multifunctional nanoliposomes for brain targeting: Potential for AD and related pathologies”
  38. International conference on NPMED (Nanoparticles and Nanotechnologies in Medicine) 2013, June 19-21, Milan, IT “Functionalization of NPs with Antibodies for therapy and diagnosis of AD: In vitro and in vivo studies
  39. LIPOSOME ADVANCES. London, 14-17 December, 2013Multiligand/Multifunctional nanoliposomes for brain and amyloid peptide targeting
  40. International Meeting for the Foundation of WanJiaYuan International Geriatric Hospital, NanYang, Henan, China, Oct 3-5 2013Multifunctional Liposomes for Brain Targeting
  41. 1st Israel-Greece joint meeting on Nanotechnology and BioNanoscience, The David Lopatie Conf. Center, Weismann Institute, Israel, 20-23/10/ 2014Nanoliposomes for therapy and/or diagnosis of AD: Latest progress
  42. Aegean Retina XIV, Mykonos, July 2015Liposomal formulations for ocular delivery: Prolonging the release of actives
  43. 9th International Symposium on Intelligent DDS 16—17 April 2015, Seoul Korea, “Nanomedicines for diagnosis/therapy of neuro-degenerative diseases: Possibilities and  Challenges
  44. 1st Panhellenic Conference on Applied Pharmaceutics, April 23-25, 2015, Thessaloniki, GR; “Nanomedicine for diagnosis and/or Therapy”
  45. The 2015 Alzheimer’s Disease Congress: 23rd – 25th June 2015, LONDON, UK, “Nanoliposomes for diagnosis/therapy of AD: Recent Progress
  46. 1st International Congress of CRS-Greek Local Chapter, May 27-28, 2015, Athens, GR. “Advanced drug delivery systems for small molecules and biotechnological drugs: differences and similarities
  47. CRS International WORKSHOP, November 2015 ,Naples, IT, “Multifunctional nanoliposomes for targeting amyloids in the brain
  48. Liposome Advances, Internation Liposome Society, Dec.18-22, 2015, London, UK. “Brain Targeted Liposomes“
  49. 2nd Internationl Conference of Greek Local CRS Chapter, 22-24 June, 2016, Athens GR; “From Liposomes to Exosomes”
  50. Nanomedicines Viterbo 2016 (CNR IT), 21-23/9, 2016, Rome, IT “Targeting with liposomes or Exosomes?”
  51. 3rd Panhellenic Pharmaceutical Sciences Conference, Thessaloniki Greece, 18-19/2/2017 ; “Cellular or Exosomal nanovesicles for drug targeting”
  52. 3rd Panhellenic Conference on Applied Pharmaceutics, May 6, 2017, Thessaloniki, GR; “Current advancements in drug targeting with nanocarriers: What cen we learn from exosomes?”
  53. 3rd International Congress of CRS-Greek Local Chapter, June 19-20, 2017, Athens, GR “Nanotechnological approaches for delivery and targeting of biological drugs”
  54. ILS & Liposome Days Conference, September Athens, GR, 2017Targeting the brain with Liposomes. What we have learned after 5 years of studies
  55. International Conference “Phytocosmetics”, July, 2017, Patras, GR. “Advanced formulation strategies for phytocosmetic /phytotherapeutic active ingredients with the application of nanotechnology
  56. LIPIDS and BRAIN IV – LIPIDS IN ALZHEIMER DISEASE, 8-12 October, 2017 Nancy, FR,”Nanoparticle based drug delivery systems crossing blood brain barrier
  57. ADVANCED SCHOOL IN NANOMEDICINES Pula, Sardinia, IT, 25-28 September 2017Functionalized liposomes for BRAIN targeting: potential solutions to a problem of 30 years”
  58. Labroots Virtual Conference Drug Discovery 2018 FEB 21 – 22; “Liposomes for Drug Delivery and Targeting: Examples of their potential from our laboratories research”
  59. 1st EMJMD NANOMED WORKSHOP, July 12-13, 2018, Paris; “Engineered cellular vesicles as drug carriers: On the way to a new generation of liposomes for efficient targeting of drugs?”
  60. ICONAN, Sept 26-28, Rome, IT, 2018 (Plenary Speaker)“Nanomedicines:Advantages, Accomplishments and Challenges”
  61. 1st NanoBio, 24-28 Sept 2018, Crete; “Engineered cellular vesicles as targeted drug carriers: towards the development of a new generation of liposomes for efficient targeted drug delivery?”
  62. Laser Applications in Life Sciences (LALS) 2018, Bar Ilan, Israel, Nov. 2018; “Liposomes and Exosome for Drug Targeting Applications: The current challenges and the need for improved imaging technologies
  63. 5th Panhellenic Conference on Applied Pharmaceutics, May 18, 2019, Thessaloniki, GR; “Novel approaches for drug targeting using nanotechnologies”
  64. ISM2019, 53rd annual meeting of the Israel Society for Microscopy, May 28, 2019, Bar Ilan, Israel; “Morphological assessment of liposomes and other types of vesicles. Current needs in the nanomedicine/drug-delivery system field”
  65. Invited Seminar at University of BarIlan, Department of Chemistry and NanoCenter, May 30, 2019; “Cellular vesicles for targeted drug delivery? New Insights”
  66. 6th Annual PCS Conference on Cancer, Nov.15-16 2019, Athens, GR; “Lipid-Based targeted Nanomedicines as cancer theragnostic systems”
MENTORING -Major contributions to the early careers of researchers
I have mentored/supervised:
  • >150 completed Pharmacy Student Diploma Theses
  • 23 Master Theses
  • 10 PhDs
  • 6 Post-Doc Researchers
  • and I am currently supervising 4 Pharmacy Diploma students; 5 Master students; 5 PhD students and 4 Post-Doc Scientists
The following professionals/researchers have been trained by me at MSc, PhD or Post-Doc level:
PhD students:
 D.G Fatouros, AUTH, Pharmacy, Thessaloníki, GR; Current position: Associate Professor (;
 P. Kallinteri, Lecturer Medway Univeristy, UK (3 Y), University of Helsinki, Faculty of Pharmacy, current: Pharmacist (Proviisori)/Previously worked as academic with expertise in the area of drug delivery.
O. Gortzi, Techn, Educational Institute of Thessaly, Department of Food Technology, Lárisa, GR. Current position: Head of the Nutrition and Dietetics department (;
 V. Ntimenou, Business Analyst in Post Onboarding Client Management team, Barclays Investments Bank, London, UK,
P. Zagana, Currently working as a Post-doc Research Assistant
 E. Markoutsa University of South Florida, Dept of Internal Medicine, Tampa, FL, USA; Current position: Adjunct Faculty (
 A. Skouras, Lecturer of Pharmaceutical Technology at European University Cyprus, Cyprus
K. Papadia, Clinical Development Scientist at Lamda Laboratories (a Clinigen Company),
K. Pachis, Pharmaceutical Development Manager, Laboserve - Pharmaceutical Company, Greece,
MSc Students:
 M. Kokona, Pharmacy Owner, Greece
 V.A. Tsotas, Pharmacy Owner, Greece
 P. Hatzi, Pharmacy Owner, Greece
 S. Piperoudi, Senior Regulatory Affairs Consultant at Pharmassist LTD, Athens, Greece,
M. Kastellorizios, Biorasis, Inc. USA, Current position: Director of R&D (;
 M. Chaikou, Novartis Pharma AG, Basel Area, Switzerland, Current position: Senior Scientist in Biopharmaceutical Process and Drug Product Development, (
Post-Doc Scientists:
 Anna Niarakis Université d'Évry-Val-d'Essonne, Département de Biologie, Évry, FR, Current position Maître de Conferences (
 Katerina Lalatsa, Senior Lecturer, University of Potrsmouth, UK,
Nikolitsa Nomikou, Associate Professor, Department of Surgical Biotechnology, Div of Surgery & Interventional Sci, Faculty of Medical Sciences, UCL, London, UK,

Ώρες υποδοχής Προπτυχιακών Φοιτητών 
 Τρίτη, Τετάρτη & Παρασκευή  12-13 π.μ